ACADIA Pharmaceuticals Inc. (ACAD) Stock Price Today
Aura AI Summary
Key Stats
- $5.02BMarket Cap
- -Volume
- HealthSector
- $30.5752W High
- $20.0652W Low
- -Typical Hold Time
- $4.13BEnterprise Value
- -Div Yield
- -Trading Activity
Track ACADIA Pharmaceuticals Inc. (ACAD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, ACADIA Pharmaceuticals Inc. has traded between a low of $20.06 and a high of $30.57, highlighting its annual price range. Buy and sell ACADIA Pharmaceuticals Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Most Recent News
Centrica shifts to focused energy firm with growth potential despite risks and sector discount
Centrica, a British utility in the FTSE 100, is transforming into a focused, integrated energy company with improving earnings quality and a more attractive core business. The company trades at a significant discount compared to peers due to risks fr...
High-yield dividend stocks yield 6%+ and grow tax-free in Roth IRAs, boosting long-term returns.
Certain high-yield dividend stocks, including BDCs and MLPs, generate ordinary income taxed heavily in taxable accounts but grow tax-free in Roth IRAs. Stocks like Enterprise Products Partners, MPLX, Ares Capital, and Blue Owl Capital yield between 5...
Texas Instruments posts strong Q2 growth, price hikes return amid chip demand recovery
Texas Instruments reported strong growth in Q2, with its Analog segment revenue rising 26% year over year, signaling a recovery from a prolonged downturn in industrial and automotive markets. The company has regained pricing power, implementing its f...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.